Literature DB >> 24217699

Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers.

Florian M E Wagenlehner1, Fabian Münch, Adrian Pilatz, Birte Bärmann, Wolfgang Weidner, Christine M Wagenlehner, Marion Straubinger, Holger Blenk, Wolfgang Pfister, Michael Kresken, Kurt G Naber.   

Abstract

Because of the increasing bacterial resistance of uropathogens against standard antibiotics, such as trimethoprim (TMP), older antimicrobial drugs, such as nitroxoline (NTX), should be reevaluated. This randomized crossover study investigated the urinary concentrations of parent drugs and their metabolites and their antibacterial activities (urinary inhibitory titers [UITs] and urinary bactericidal titers [UBTs]) against uropathogens at three different urinary pH values within 24 h in six healthy volunteers after a single oral dose of NTX at 250 mg versus TMP at 200 mg. In three additional volunteers, urinary bactericidal kinetics (UBK) were studied after oral administration of NTX at 250 mg three times a day. The mean urinary concentrations of NTX and NTX sulfate in 24 h were 0.012 to 0.507 mg/liter and 0.28 to 27.83 mg/liter, respectively. The mean urinary concentrations of TMP were 18.79 to 41.59 mg/liter. The antibacterial activity of NTX was higher in acidic urine than in alkaline urine, and that of TMP was higher in alkaline urine than in acidic urine. The UITs and UBTs of NTX were generally lower than those of TMP except for a TMP-resistant Escherichia coli strain, for which NTX showed higher UITs/UBTs than did TMP. UBK showed mainly bacteriostatic activity of NTX in urine. NTX exhibits mainly bacteriostatic activity and TMP also shows bactericidal activity in urine against susceptible strains. NTX is a more active antibacterial in acidic urine, and TMP is more active in alkaline urine. The cumulative effects of multiple doses or inhibition of bacterial adherence could not be evaluated. (This study has been registered at EudraCT under registration no. 2009-015631-32.).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24217699      PMCID: PMC3910821          DOI: 10.1128/AAC.02147-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

Review 1.  On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications.

Authors:  Stefan Wellek; Maria Blettner
Journal:  Dtsch Arztebl Int       Date:  2012-04-13       Impact factor: 5.594

Review 2.  [S3-guideline for uncomplicated urinary tract infections - treatment guidelines compliance].

Authors:  Florian M E Wagenlehner; Guido Schmiemann; Udo Hoyme; Reinhard Fünfstück; Eva Hummers-Pradier; Martin Kaase; Eberhard Knieh; Isolde Selbach; Urban Sester; Winfried Vahlensieck; Dirk Watermann; Kurt G Naber
Journal:  Med Monatsschr Pharm       Date:  2011-05

Review 3.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

4.  Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited.

Authors:  Gunnar Kahlmeter; Hanna Odén Poulsen
Journal:  Int J Antimicrob Agents       Date:  2011-11-03       Impact factor: 5.283

5.  Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA).

Authors:  J W Warren; E Abrutyn; J R Hebel; J R Johnson; A J Schaeffer; W E Stamm
Journal:  Clin Infect Dis       Date:  1999-10       Impact factor: 9.079

6.  Uncomplicated urinary tract infections.

Authors:  Florian M E Wagenlehner; Udo Hoyme; Martin Kaase; Reinhard Fünfstück; Kurt G Naber; Guido Schmiemann
Journal:  Dtsch Arztebl Int       Date:  2011-06-17       Impact factor: 5.594

7.  Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.

Authors:  Florian M E Wagenlehner; Stephan Wydra; Hajime Onda; Martina Kinzig-Schippers; Fritz Sörgel; Kurt G Naber
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project.

Authors:  G Kahlmeter
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

9.  The urinary antibiotic 5-nitro-8-hydroxyquinoline (Nitroxoline) reduces the formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc.

Authors:  A Sobke; M Klinger; B Hermann; S Sachse; S Nietzsche; O Makarewicz; P M Keller; W Pfister; E Straube
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

10.  Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.

Authors:  Kurt G Naber; Giancarlo Schito; Henry Botto; Juan Palou; Teresita Mazzei
Journal:  Eur Urol       Date:  2008-05-21       Impact factor: 20.096

View more
  20 in total

1.  In vitro activity of nitroxoline against Escherichia coli urine isolates from outpatient departments in Germany.

Authors:  Michael Kresken; Barbara Körber-Irrgang
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

2.  [Candiduria! What now? : Therapy of urinary tract infections with Candida].

Authors:  H Hof
Journal:  Urologe A       Date:  2017-02       Impact factor: 0.639

3.  [Nitroxoline - an option for the antibiotic treatment of urinary tract infections].

Authors:  H Hof; D Bertsch; D Passek; R Schwarz
Journal:  Urologe A       Date:  2017-02       Impact factor: 0.639

Review 4.  [Community acquired urinary tract infections - association with risk factors : Changes in causative organisms and resistance over time].

Authors:  B Ubrig; M Böhme; A Merklinghaus; F Wagenlehner
Journal:  Urologe A       Date:  2017-06       Impact factor: 0.639

5.  In vitro activity of mecillinam, temocillin and nitroxoline against MDR Enterobacterales.

Authors:  Lars Plambeck; Frieder Fuchs; Janko Sattler; Axel Hamprecht
Journal:  JAC Antimicrob Resist       Date:  2022-06-16

6.  Nitroxoline: an option for the treatment of urinary tract infection with multi-resistant uropathogenic bacteria.

Authors:  Herbert Hof; C Juretschke
Journal:  Infection       Date:  2018-11-17       Impact factor: 3.553

7.  Analogs of nitrofuran antibiotics are potent GroEL/ES inhibitor pro-drugs.

Authors:  Mckayla Stevens; Chris Howe; Anne-Marie Ray; Alex Washburn; Siddhi Chitre; Jared Sivinski; Yangshin Park; Quyen Q Hoang; Eli Chapman; Steven M Johnson
Journal:  Bioorg Med Chem       Date:  2020-08-30       Impact factor: 3.641

8.  Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in an In Vitro Model of Intracellular Infection.

Authors:  Françoise Van Bambeke; Marta Putrinš; Ivana Kerkez; Paul M Tulkens; Tanel Tenson
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191

9.  Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records.

Authors:  Jacob J Hughey; Jennifer M Colby
Journal:  Clin Chem       Date:  2019-10-02       Impact factor: 12.167

10.  Compared with Cotrimoxazole Nitroxoline Seems to Be a Better Option for the Treatment and Prophylaxis of Urinary Tract Infections Caused by Multidrug-Resistant Uropathogens: An In Vitro Study.

Authors:  Ulrich Dobrindt; Haleluya T Wami; Torsten Schmidt-Wieland; Daniela Bertsch; Klaus Oberdorfer; Herbert Hof
Journal:  Antibiotics (Basel)       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.